Home
BCAB

BCAB

BioAtla Inc.

as of 12-09-2025 4:00pm EST

$0.81

$0.00

-0.58%

Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.

Chart Type:

Time Range:

Founded:	2007	Country:	United States
Employees:	N/A	City:	SAN DIEGO
Market Cap:	71.6M	IPO Year:	2020
Target Price:	$1.00	AVG Volume (30 days):	2.1M
Analyst Decision:	Hold	Number of Analysts:	3
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-1.15	EPS Growth:	N/A
52 Week Low/High:	$0.24 - $1.72	Next Earning Date:	11-13-2025
Revenue:	N/A	Revenue Growth:	N/A
Revenue Growth (this year):	N/A	Revenue Growth (next year):	N/A

AI-Powered BCAB Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold

Model Accuracy: 70.14%

70.14%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full BCAB Forecast & Prediction with Hourly Data

Compare BCAB vs Leading Stocks

See how BCAB stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free BCAB Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "BCAB BioAtla Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.